Therapeutic potential of Toll-like receptor 9 activation
Top Cited Papers
- 1 June 2006
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 5 (6) , 471-484
- https://doi.org/10.1038/nrd2059
Abstract
In the decade since the discovery that mouse B cells respond to certain unmethylated CpG dinucleotides in bacterial DNA, a specific receptor for these 'CpG motifs' has been identified, Toll-like receptor 9 (TLR9), and a new approach to immunotherapy has moved into the clinic based on the use of synthetic oligodeoxynucleotides (ODN) as TLR9 agonists. This review highlights the current understanding of the mechanism of action of these CpG ODN, and provides an overview of the preclinical data and early human clinical trial results using these drugs to improve vaccines and treat cancer, infectious disease and allergy/asthma.Keywords
This publication has 188 references indexed in Scilit:
- Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNANature Immunology, 2005
- A Toll-like receptor–independent antiviral response induced by double-stranded B-form DNANature Immunology, 2005
- Spatiotemporal regulation of MyD88–IRF-7 signalling for robust type-I interferon inductionNature, 2005
- Spontaneous Formation of Nucleic Acid-based Nanoparticles Is Responsible for High Interferon-α Induction by CpG-A in Plasmacytoid Dendritic CellsJournal of Biological Chemistry, 2005
- Immunology of hepatitis B virus and hepatitis C virus infectionNature Reviews Immunology, 2005
- Toll-like receptor control of the adaptive immune responsesNature Immunology, 2004
- An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirusNature Medicine, 2004
- Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenograftsEuropean Journal Of Cancer, 2004
- TLR9 signals after translocating from the ER to CpG DNA in the lysosomeNature Immunology, 2004
- Evaluation of the Toxicity of ISIS 2302, a Phosphorothioate Oligonucleotide, in a 4-Week Study in CD-1 MiceAntisense and Nucleic Acid Drug Development, 1997